Regeneron Pharmaceuticals, Inc. $REGN is Tamar Securities LLC’s 8th Largest Position

Tamar Securities LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 40,456 shares of the biopharmaceutical company’s stock after buying an additional 8,190 shares during the quarter. Regeneron Pharmaceuticals comprises 3.3% of Tamar Securities LLC’s portfolio, making the stock its 8th largest holding. Tamar Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $31,227,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Insigneo Advisory Services LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.0% in the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 13 shares during the period. TD Private Client Wealth LLC boosted its stake in shares of Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 15 shares during the period. MCF Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 15 shares during the period. CYBER HORNET ETFs LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.0% in the 4th quarter. CYBER HORNET ETFs LLC now owns 301 shares of the biopharmaceutical company’s stock valued at $232,000 after buying an additional 17 shares during the period. Finally, Meyer Handelman Co. boosted its stake in shares of Regeneron Pharmaceuticals by 0.6% in the 4th quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock valued at $2,221,000 after buying an additional 18 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Sanford C. Bernstein decreased their price objective on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Royal Bank Of Canada decreased their price objective on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research note on Monday, May 18th. TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $800.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $792.65.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $612.14 on Monday. The business has a 50 day moving average price of $692.11 and a 200 day moving average price of $738.00. The stock has a market cap of $64.72 billion, a price-to-earnings ratio of 14.92, a PEG ratio of 1.34 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $503.25 and a fifty-two week high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $8.22 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.